High Blood Pressure in Young Adults Could Mean Heart Trouble in Middle Age

February 5, 2014

High_Blood_PressureFeb 5: Twenty-somethings with even mildly elevated blood pressure may face an increased risk of clogged heart arteries by middle age, a long-term U.S. study finds.

The study, which tracked nearly 4,700 people, found that even "pre-hypertension" in young adulthood was linked to a higher risk of calcium buildup in the heart arteries 25 years later.

Experts said the findings send a message to young adults: Know your blood pressure numbers and, if needed, change your lifestyle to get them in the normal range.

"What you do as a young adult matters," said lead researcher Norrina Allen, an assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine, in Chicago. "We shouldn't wait until middle-age to address blood pressure."

That same message goes for doctors, too, Allen added. "Many doctors might not think a small elevation in blood pressure (in a young adult) even warrants a discussion," she said.

The new study appears in the Feb. 5 issue of the Journal of the American Medical Association.

The good news, Allen noted, is that lifestyle changes can "absolutely" be enough for a healthy young person with moderately elevated blood pressure.

An expert not involved in the study agreed. "Lifestyle changes do work. Even within the span of a few months, blood pressure can dramatically improve," said Dr. George Bakris, a professor of medicine at University of Chicago Medicine who wrote an editorial published with the study.

Diet changes, such as cutting out salty processed foods and getting more fruits and vegetables, are key. So is moderate exercise, like walking, study author Allen said. And if you're overweight, even cutting a few pounds can help lower blood pressure.

Bakris pointed to some steps that are less well known: Watch your drinking, since alcohol can raise blood pressure; and get enough sleep.

"It's important to get at least six hours of uninterrupted sleep each night," Bakris said. "Ideally, you'd get six to eight hours."

In the United States, about one-third of adults have high blood pressure, which is defined as a systolic pressure (the top number) of 140 or higher, or a diastolic pressure (the bottom number) of 90 or higher, according to the U.S. Centers for Disease Control and Prevention. "Normal" blood pressure is anything below 120/80, while numbers that fall in between "normal" and "high" are considered "pre-hypertension."

The new findings are based on 4,681 people from four U.S. cities who were between the ages of 18 and 30 when they entered the study in the mid-1980s. Over the next couple of decades, they had their blood pressure taken periodically. At year 25, they underwent CT scans to look for calcium buildup in the arteries -- which is considered an early sign of heart disease.

Overall, Allen's team found that study participants had five general "trajectories" in blood pressure over time.

Five percent had slightly elevated blood pressure at their first measurement, which then kept increasing over the years. That group had the worst-looking arteries 25 years later: One-quarter had calcium "scores" above 100, which is linked to a higher-than-normal risk of suffering a heart attack in the next several years.

In contrast, among people who had normal blood pressure throughout the study, only 4 percent had calcium scores that high.

But it wasn't only the young people with ever-increasing blood pressure who showed artery trouble later on.

Another 19 percent had blood pressure that was slightly elevated in young adulthood, but stable thereafter -- hovering in the pre-hypertension range over the years. In that group, 17 percent ended up with a calcium score above 100.

Of course, young people with elevated blood pressure might have other health issues, too. But even when Allen's team took into account for other factors -- like smoking, weight and current blood pressure -- a person's lifetime blood-pressure pattern was still important.

According to Bakris, it all suggests that elevated blood pressure, left unchecked, can start taking a toll on the arteries early in life. "If you wait until your 40s or 50s to address it, the damage to the arteries may already be done," he said.

He suggested that most healthy young people have their blood pressure checked every couple of years. But if they have a strong family history of high blood pressure -- such as two parents who developed the condition at a fairly young age -- more-frequent blood pressure checks would be in order, Bakris said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 2,2020

The American pharmaceutical giant Pfizer Inc. and the European biotechnology company BioNTech SE have conducted an experimental trial of a COVID-19 vaccine candidate and found it to be safe, well-tolerated, and capable of generating antibodies in the patients.

The study, which is yet to be peer-reviewed, describes the preliminary clinical data for the candidate vaccine -- nucleoside-modified messenger RNA (modRNA), BNT162b1.

It said the amount of antibodies produced in participants after they received two shots of the vaccine candidate was greater than that reported in patients receiving convalescent plasma from recovered COVID-19 patients.

"I was glad to see Pfizer put up their phase 1 trial data today. Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers," tweeted Peter Hotez, a vaccine scientist from Baylor College of Medicine in the US, who was unrelated to the study.

Researchers, including those from New York University in the US, who were involved in the study, said the candidate vaccine enables human cells to produce an optimised version of the receptor binding domain (RBD) antigen -- a part of the spike (S) protein of SARS-CoV-2 which it uses to gain entry into human cells.

"Robust immunogenicity was observed after vaccination with BNT162b1," the scientists noted in the study.

They said the program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target component of the novel coronavirus, SARS-CoV-2.

Based on the study's findings, they said BNT162b1 could be administered in a quantity that was well tolerated, potentially generating a dose dependent production of immune system molecules in the patients.

The research noted that patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of RBD-binding antibodies that could neutralise SARS-CoV-2.

"We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings," said Kathrin U. Jansen, study co-author and Senior Vice President and Head of Vaccine Research & Development, Pfizer.

"We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible," Jansen said.

According to Ugur Sahin, CEO and Co-founder of BioNTech, and another co-author of the study, the preliminary data are encouraging as they provide an initial signal that BNT162b1 is able to produce neutralising antibody responses in humans.

He said the immune response observed in the patients treated with the experimental vaccine are at, or above, the levels observed from convalescent sera, adding that it does so at "relatively low dose levels."

"We look forward to providing further data updates on BNT162b1," Sahin said.

According to a statement from Pfizer, the initial part of the study included 45 healthy adults 18 to 55 years of age.

It said the priliminary data for BNT162b1 was evaluated in 24 subjects who received two injections of 10 microgrammes ( g) and 30 g -- 12 subjects who received a single injection of 100 g, and 9 subjects who received two doses of a dummy vaccine.

The study noted that participants received two doses, 21 days apart, of placebo, 10 g or 30 g of BNT162b1, or received a single dose of 100 g of the vaccine candidate.

According to the scientists, the highest neutralising concentrations of antibodies were observed seven days after the second dose of 10 g, or 30 g on day 28 after vaccination.

They said the neutralising concentrations were 1.8- and 2.8-times that observed in a panel of 38 blood samples from people who had contracted the virus.

In all 24 subjects who received two vaccinations at 10 g and 30 g dose levels, elevation of RBD-binding antibody concentrations was observed after the second injection, the study noted.

It said these concentrations are 8- and 46.3-times the concentration seen in a panel of 38 blood samples from those infected with the novel coronavirus.

At the 10 g or 30 g dose levels, the scientists said adverse reactions, including low grade fever, were more common after the second dose than the first dose.

According to Pfizer, local reactions and systemic events after injection with 10 g and 30 g of BNT162b1 were "dose-dependent, generally mild to moderate, and transient."

It said the most commonly reported local reaction was injection site pain, which was mild to moderate, except in one of 12 subjects who received a 100 g dose, which was severe.

The study noted that there was no serious adverse events reported by the patients.

Citing the limitations of the research, the scientists said the immunity generated in the participants in the form of the T cells and B cells of their immune system, and the level of immunity needed to protect one from COVID-19 are unknown.

With these preliminary data, along with additional data being generated, Pfizer noted in the statement that the two companies will determine a dose level, and select among multiple vaccine candidates to seek to progress to a large, global safety and efficacy trial, which may involve up to 30,000 healthy participants if regulatory approval to proceed is received.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 2,2020

London, Jul 2: The World Health Organisation says smoking is linked to a higher risk of severe illness and death from the coronavirus in hospitalised patients, although it was unable to specify exactly how much greater those risks might be.

In a scientific brief published this week, the U.N. health agency reviewed 34 published studies on the association between smoking and Covid-19, including the probability of infection, hospitalisation, severity of disease and death.

WHO noted that smokers represent up to 18% of hospitalised coronavirus patients and that there appeared to be a significant link between whether or not patients smoked and the severity of disease they suffered, the type of hospital interventions required and patients' risk of dying.

In April, French researchers released a small study suggesting smokers were at less risk of catching Covid-19 and planned to test nicotine patches on patients and health workers — but their findings were questioned by many scientists at the time who cited the lack of definitive data.

WHO says "the available evidence suggests that smoking is associated with increased severity of disease and death in hospitalized Covid-19 patients. It recommends that smokers quit.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 30,2020

New York, Jul 30: Can the coronavirus spread through the air? Yes, it's possible.

The World Health Organisation recently acknowledged the possibility that Covid-19 might be spread in the air under certain conditions.

Recent Covid-19 outbreaks in crowded indoor settings — restaurants, nightclubs and choir practices — suggest the virus can hang around in the air long enough to potentially infect others if social distancing measures are not strictly enforced.

Experts say the lack of ventilation in these situations is thought to have contributed to spread, and might have allowed the virus to linger in the air longer than normal.

In a report published in May, researchers found that talking produced respiratory droplets that could remain in the air in a closed environment for about eight to 14 minutes.

The WHO says those most at risk from airborne spread are doctors and nurses who perform specialized procedures such as inserting a breathing tube or putting patients on a ventilator.

Medical authorities recommend the use of protective masks and other equipment when doing such procedures.

Scientists maintain it's far less risky to be outside than indoors because virus droplets disperse in the fresh air, reducing the chances of Covid-19 transmission.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.